Abbott Laboratories (ABT.N): HSKT Call Series: Setting the Stage for an Eventful 2027

Research evidence excerpt

Abbott Laboratories (ABT.N): HSKT Call Series: Setting the Stage for an Eventful 2027

Flash |

03 Aug 2026 16:26:43 ET │ 11 pages

Abbott Laboratories (ABT.N)

HSKT Call Series: Setting the Stage for an Eventful 2027

CITI'S TAKE

Buy Following a stronger-than-expected 2Q26, we hosted our HSKT call with

Lisa Earnhardt, EVP of Medical Devices at Abbott, where we parsed Price (03 Aug 26 13:03) US$106.88

through its pipeline that should position it for accelerating growth in Target price US$112.00

2H26+. The call centered on high growth areas, highlighting clinical and Expected share price return 4.8%

commercial launches, including: 1) launching Volt and TactiFlex Duo in Expected dividend yield 1.3%

Europe and expanding Volt in the U.S. (TactiFlex Duo in the U.S. 2027E); 2) Expected total return 6.1%

additional navigation and ancillary products in EP, including a new ICE

Market Cap US$184,943M catheter and new introducer sheath; 3) 4Q26 FDA approval for next-gen

Amulet 360 (if not then, in 1Q27); 4) initiating several pivotal trials,

including for Cephea mitral replacement valve, balloon-expandable TAVR

valve, Aveir conduction system pacing (CSP), and peripheral IVL; 5) OUS Joanne WuenschAC

launch of dual-sensing Libre Duo 2H26 and FDA approval in 2H26E; and +1-212-816-9606

6) expansion of CMS CGM coverage for Type 2 non-insulin intensive joanne.wuensch@citi.com

patients. We rate ABT Buy/Top Pick.

Anthony Occhiogrosso

+1-212-816-7579

Diving into the increasingly competitive PFA market. Abbott is expanding its anthony.occhiogrosso@citi.com

footprint in the Electrophysiology (EP) market, building on its market leading EnSite

Jane-Marie Lai

mapping and navigation system (which benefited from being an open system when

+1-212-816-3628

the company did not have a PFA catheter).